Phase 1 (Safety and Dosage)

Many drug development programs begin with intravenous (IV) formulations in Phase 1 to ensure controlled delivery and avoid bioavailability uncertainties. However, most commercial drugs aim for oral delivery due to patient convenience and lower costs. The transition from IV to oral forms—known as formulation bridging—requires careful planning, PK comparison, and regulatory strategy. This article explores how clinical teams bridge formulations effectively during early development, ensuring a smooth progression toward later-phase trials and eventual approval.
Click to read the full article.

Phase 1 clinical trials are dynamic, fast-paced, and data-intensive. These early studies demand close oversight of safety signals, pharmacokinetic (PK) parameters, and operational compliance. Traditional data collection and monitoring methods—dependent on batch uploads, manual reviews, and delayed visibility—are being replaced by real-time data monitoring platforms. These advanced digital tools provide instantaneous access to clinical data, enabling rapid decision-making, proactive safety management, and improved trial efficiency. This tutorial explores the architecture, benefits, regulatory expectations, and implementation strategies of real-time monitoring solutions in Phase 1 trials.
Click to read the full article.

Informed consent is a cornerstone of ethical clinical research, but its implementation becomes significantly more complex in high-risk Phase 1 trials. These early-stage studies often involve first-in-human (FIH) dosing, novel mechanisms, limited preclinical safety data, and uncertain risk profiles. Participants may be healthy volunteers or vulnerable patients, and consent forms can span dozens of pages filled with technical language. Ensuring comprehension, voluntariness, and ethical transparency becomes not only a regulatory requirement but a moral imperative. This article explores the unique challenges of informed consent in high-risk early-phase trials and provides strategies for improving clarity, compliance, and participant protection.
Click to read the full article.

Cell and gene therapies (CGTs) represent one of the most revolutionary frontiers in medicine, offering curative potential for genetic disorders, cancers, and rare diseases. However, these therapies bring profound challenges when it comes to designing early-phase clinical trials. Phase 1 studies must accommodate long-term risks, novel delivery mechanisms, complex manufacturing logistics, and regulatory scrutiny. In this tutorial, we explore how to design scientifically sound and ethically responsible Phase 1 trials for cell and gene therapies, covering dose escalation, safety considerations, and global regulatory frameworks.
Click to read the full article.

Cardiac safety assessment is a critical component of Phase 1 clinical trials, particularly for new chemical entities and biologics with unknown off-target effects. One of the primary concerns is QT interval prolongation—a surrogate marker for the risk of Torsades de Pointes and sudden cardiac death. Phase 1 studies typically include intensive ECG monitoring to detect such changes early. This article outlines best practices, regulatory expectations, and technical strategies for cardiac safety monitoring, with a focus on QTc evaluation, ECG scheduling, and data interpretation.
Click to read the full article.

Inhalation drug delivery offers fast, localized therapeutic action with minimal systemic exposure. Used in respiratory diseases like asthma and COPD, and increasingly in systemic applications such as vaccines or insulin, inhaled therapies pose unique clinical challenges in early development. Phase 1 trials for inhaled products must evaluate not just safety and pharmacokinetics (PK), but also drug-device compatibility, pulmonary deposition, and inhalation technique. This tutorial provides a comprehensive guide to designing Phase 1 studies for inhaled drugs, covering PK/PD strategies, device testing, and regulatory expectations.
Click to read the full article.

Predicting a safe and pharmacologically relevant starting dose is one of the most critical decisions in early-phase clinical development. Pharmacometrics—the science of applying mathematical modeling and simulation to pharmacokinetic (PK) and pharmacodynamic (PD) data—plays a vital role in guiding dose selection, estimating exposure, and anticipating human variability before entering Phase 1. This tutorial explores how pharmacometric approaches such as allometric scaling, physiologically based pharmacokinetic (PBPK) modeling, and population PK (PopPK) support early trial design, reduce risk, and enhance regulatory confidence.
Click to read the full article.

Phase 1 clinical trials are no longer limited to safety and pharmacokinetics. With the evolution of precision medicine, biomarkers have become essential tools in early development to characterize mechanism of action, monitor biological response, and support rational dose selection. Two major types of biomarkers—exploratory and predictive—are frequently integrated into Phase 1 protocols to bridge preclinical data with clinical outcomes. This article explains how to build a biomarker strategy in Phase 1 trials, the key differences between biomarker types, and how they align with regulatory expectations.
Click to read the full article.

The intersection of drugs and medical devices in a single product—known as a drug-device combination (DDC)—is transforming how therapies are delivered across areas like diabetes, asthma, oncology, and pain management. In early development, these products require integrated evaluation of device usability, drug delivery, and clinical performance. Planning a Phase 1 trial for a combination product involves navigating dual regulatory frameworks, conducting device-specific usability testing, and ensuring that drug pharmacokinetics are not compromised by delivery mechanics. This article offers a detailed guide to designing successful early-phase studies for combination products.
Click to read the full article.

In Phase 1 trials, where safety and pharmacokinetics are the primary goals, blinding and randomization might seem optional. However, these design elements are essential for minimizing bias, ensuring interpretability, and supporting regulatory credibility—even in early development. Whether you’re conducting single ascending dose (SAD), multiple ascending dose (MAD), or food-effect studies, applying appropriate blinding and randomization safeguards the objectivity of the trial outcomes. This tutorial explores best practices for implementing these features in Phase 1 studies and highlights their operational and ethical implications.
Click to read the full article.